Table 3.
Hazard ratios (95% confidence intervals) for development of 50% decline in eGFR or KRT (transplant or dialysis) among 603 children with nonglomerular disease contributing 2673 person-years of follow-up and 190 composite events
| Serum Bicarbonate | Model 1 | Model 2 | Model 3 | Model 4 |
|---|---|---|---|---|
| Baseline bicarbonate | ||||
| >22 meq/L | 1 | 1 | 1 | 1 |
| 19–22 meq/L, HR (95% CI) | 1.85 (1.35 to 2.52)a | 1.17 (0.84 to 1.62) | 1.14 (0.82 to 1.58) | 1.13 (0.80 to 1.59) |
| ≤18 meq/L, HR (95% CI) | 5.60 (3.65 to 8.58)a | 2.20 (1.40 to 3.43)a | 1.91 (1.21 to 3.02)a | 1.95 (1.23 to 3.09)a |
| Time-varying bicarbonate | ||||
| >22 meq/L | 1 | 1 | 1 | 1 |
| 19–22 meq/L, HR (95% CI) | 1.71 (1.24 to 2.35)a | 1.13 (0.81 to 1.57) | 0.89 (0.64 to 1.25) | 0.91 (0.65 to 1.26) |
| ≤18 meq/L, HR (95% CI) | 4.01 (2.70 to 5.95)a | 1.87 (1.45 to 2.82)a | 1.29 (0.85 to 1.96) | 1.28 (0.84 to 1.94) |
Model 1: unadjusted model. Model 2: model 1 plus adjustment for baseline age (centered at 10), male sex, white race, baseline eGFR (<30, 30–45, 45–60, or ≥60 ml/min per 1.73 m2), and proteinuria (< 0.5, 0.5–2.0, or ≥2.0 mg/mg). Model 3: model 2 plus adjustment for anemia and phosphate (centered at 4.5 mg/dl). Model 4: model 3 plus adjustment for hypertension and alkali therapy use. HR, hazard ratio; 95% CI, 95% confidence interval.
aIndicates significance.